SCHEMBL1455767

SCHEMBL1455767

COc1ccc(C(=O)Nc2ccc(Sc3ccc(O)cc3)c(Nc3ncnc4ncccc34)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.46
AKT2 P31751 1/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
MAPK14 Q16539 2/20 0.43
EGFR P00533 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 2/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
TP53 P04637 1/20 0.42
BRAF P15056 1/20 0.41
AURKA O14965 3/20 0.41
AURKB Q96GD4 2/20 0.41
ABL1 P00519 1/20 0.41
PPARG P37231 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
NCOR2 Q9Y618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1456335 0.92 RAB9A (0.44) RAB9ANPC1MAPK14EGFRLMNA
SCHEMBL1455215 0.89 PIM1 (0.41) PIM1AKT2RAB9ANPC1MAPK14
SCHEMBL1454907 0.89 PIM1 (0.45) PIM1AKT2RAB9ANPC1MAPK14
SCHEMBL1454892 0.88 PIM1 (0.59) PIM1AKT2RAB9ANPC1MAPK14
SCHEMBL1455984 0.87 AURKA (0.42) PIM1AKT2RAB9ANPC1MAPK14
SCHEMBL1455891 0.87 PIM1 (0.48) PIM1AKT2RAB9ANPC1MAPK14
SCHEMBL1455417 0.86 BRAF (0.46) PIM1AKT2RAB9ANPC1MAPK14
SCHEMBL1454685 0.86 ABCG2 (0.43) RAB9ANPC1MAPK14LMNAMAPT
SCHEMBL1454926 0.85 MAPK14 (0.48) RAB9ANPC1MAPK14EGFRMAPT
SCHEMBL1454720 0.85 PIM1 (0.44) PIM1AKT2MAPK14EGFRABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885RAB9A 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.